DMAAU
Drugs Made In-U·NASDAQ
--
--(--)
--
--(--)
5.15 / 10
Netural
Analyst sentiment is neutral with no active analyst coverage, and fund flow evaluation registers a 5.15/10 score, showing balanced inflows and outflows across block, small, medium, large, and extra-large categories. The negative trends in most flow segments temper enthusiasm, reinforcing a neutral sentiment toward the stock.
Fund Flow Rating
What is the analyst consensus for DMAAU?
- DMAAU holds a Neutral analyst rating, with 0% of experts assigning a Hold grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 5.15/10 (Netural).
